清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Interrogating KRAS, ERK, and MYC Signaling in Pancreatic Cancer with Endogenous PET Imaging

作者
Kelly E. Henry,Megan M. Dacek,Thomas R. Dilling,Jonathan D. Caen,Michael J. Evans,Jason Stuart Lewis
摘要

72 Objectives: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers with a 5-year survival rate of less than 10%. Currently, there is a critical need for specific, clinically translatable, and non-invasive tools to assess metabolic effects, predict treatment response, and demarcate biology within pancreatic cancer. KRAS mutations have been identified in >90% of PDAC and are connected to a number of signaling pathways relevant to cancer, including mitogen-activated protein kinase (MAPK) and extracellular regulated kinase (ERK). A non-invasive biomarker to study protein signaling downstream of KRAS would greatly enhance our ability to stratify patients that will benefit from targeted therapies. There is recent literature that suggests a link between KRAS and downstream MYC signaling, but the relationship is not well understood. A key downstream event of MYC dysregulation is overexpression of the transferrin receptor (TfR), which has been targeted for cancer therapeutics and imaging. In this study, we aimed to test if zirconium-89 transferrin (89Zr[Zr]-Tf), an endogenous PET agent developed in our lab, could measure changes in MYC, depending on KRAS status of pancreatic cancer tumors. We also sought to test if anti-MYC and anti-ERK therapies could be measured with 89Zr[Zr]-Tf PET, biodistribution studies, and ex vivo immunohistochemistry. Methods: Doxycycline-inducible KRAS mutant murine cells (iKras[asterisk]p53[asterisk]) and human PDAC cell lines (Capan-2, Suit-2, MIA PaCa-2, and BxPC-3) were treated with BRD4 inhibitors JQ1 and OTX015, and ERK inhibitor SCH772984. Mice were inoculated were iKras[asterisk]p53[asterisk] tumors and human PDAC xenografts. Mice bearing iKras[asterisk]p53[asterisk] tumors were imaged with 89Zr[Zr]-Tf pre- and post-withdrawal of doxycycline dependence to observe differential uptake based on status of oncogenic KRAS. Human PDAC xenografts were administered JQ1 or SCH772984 (50 mg/kg twice daily), and PET imaging studies with 89Zr[Zr]-Tf were performed to monitor tumoral uptake and response to drug treatment. Biodistribution studies 48 h post-radiotracer administration quantified tumor and tissue uptake in each cohort. Results: A statistically significant decrease in cell proliferation and protein expression (phospho-ERK, MYC, and TfR) was observed via western blot and flow cytometry in multiple PDAC cell lines (P < 0.05-0.001) upon drug treatment. Female athymic nude were inoculated with iKras[asterisk]p53[asterisk] tumors and showed differential uptake of 89Zr[Zr]-Tf depending upon KRAS dependency, with significantly higher (P < 0.01-0.05) uptake in mice that were withdrawn from inducible oncogenic KRAS, which was confirmed by an increase in MYC and TfR protein expression via ex vivo immunohistochemistry. A therapy study with BRD4 inhibitor JQ1 showed a statistically significant decrease (P < 0.05) in 89Zr[Zr]-Tf uptake in drug vs. vehicle-treated animals bearing Capan-2 and Suit-2 (KRAS mutant) xenografts. JQ1 therapy showed no statistical difference in BxPC-3 (KRAS wild-type) xenografts, but therapy with ERK inhibitor SCH772984 (same dosing and schedule) in BxPC-3 mice showed a statistically significant decrease in 89Zr[Zr]-Tf uptake (P < 0.05) in drug vs. vehicle-treated animals. Ex vivo immunohistochemical analysis of resected human PDAC tumors reflects the data observed via PET imaging and radiotracer biodistribution. Conclusions: Our radiotracer shows promise as a tool for interrogating proteins downstream of oncogenic KRAS such as ERK and MYC via transferrin receptor in PDAC. This strategy can pave the way to assess oncogene status and predict early therapy response to targeted inhibitors in pancreatic cancer. Research Support. This research was supported by the National Institutes of Health (1R01CA17661-01), the Center for Molecular Imaging and Nanotechnology Tow Fellowship (K.E.H.), MSKCC CCSG Grant (P30 CA008748), the American Cancer Society Research Scholar Grant (130635-RSG-17-005-01-CCE), and the UCSF CCSG (P30CA082103).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
典雅的醉易完成签到,获得积分10
10秒前
冷酷紫烟完成签到,获得积分10
12秒前
深情的晓槐完成签到,获得积分10
20秒前
Aman完成签到,获得积分10
24秒前
可靠秋蝶完成签到,获得积分10
31秒前
超帅黑夜完成签到,获得积分10
35秒前
CodeCraft的应助被无限幻枫采纳,获得10
38秒前
火星上安柏完成签到,获得积分10
44秒前
50秒前
贪玩的夏真完成签到,获得积分10
56秒前
科研通AI6.4的应助被xingsixs采纳,获得10
56秒前
风中的世平完成签到,获得积分10
1分钟前
Aman完成签到,获得积分10
1分钟前
懒得起名字完成签到 ,获得积分10
1分钟前
温暖的胜完成签到,获得积分10
1分钟前
无悔完成签到 ,获得积分0
1分钟前
纯真的雁凡完成签到,获得积分10
1分钟前
柔弱的铅笔完成签到,获得积分10
1分钟前
Tracy发布了新的文献求助10
1分钟前
1分钟前
顺利夏云完成签到,获得积分10
1分钟前
xingsixs发布了新的文献求助10
1分钟前
Tracy完成签到,获得积分10
2分钟前
zwlei完成签到,获得积分10
2分钟前
腼腆的雪珊完成签到,获得积分10
2分钟前
热情的衬衫完成签到,获得积分10
2分钟前
xingsixs完成签到,获得积分10
2分钟前
危机的白凡完成签到,获得积分10
2分钟前
徐伟业完成签到 ,获得积分10
2分钟前
RetchieLi完成签到,获得积分10
2分钟前
2分钟前
无限幻枫发布了新的文献求助10
2分钟前
眼睛大的向彤完成签到,获得积分10
2分钟前
俭朴映寒完成签到,获得积分10
2分钟前
汉堡包的应助被bluemoon采纳,获得10
2分钟前
3分钟前
王磊磊0811发布了新的文献求助10
3分钟前
害羞傲安完成签到,获得积分10
3分钟前
外向夜阑完成签到,获得积分10
3分钟前
LINDENG2004完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370